Skip to main content

Pfizer guidance

  • PFE · NYSE
  • Pharmaceuticals
  • S&P 500
$28.89+0.21%Close 13 Nov 2026

In its results release of 3 Nov 2026 (Q3 FY2026), Pfizer gave 3 forecasts in figures, among them revenue of $62.00B to $64.00B for FY2026. Over the last two years, results landed above the company's own last range 1 of 3 times, within it 2 and below it 0.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 3 Nov 2026

MeasurePeriodGuidanceAs stated
RevenueFY2026$62.00B to $64.00BRevenues $62.0 to $64.0 billion
EPS · Adjusted · RaisedFY2026$2.95 to $3.05■ Raises and Narrows Full-Year 2026 Adjusted Diluted EPS Guidance to a Range of $2.95 to $3.05
Tax rateFY202615%Effective Tax Rate on Adjusted Income 15.0%

Source: the company's earnings release.

Guidance against results above 1 · within 2 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$62.00B to $64.00BRaised once—To come
EPS · AdjustedFY2026$2.95 to $3.05Raised once—To come
Tax rateFY202615%Unchanged—To come
RevenueFY2025$61.00B to $64.00BUnchanged$62.58BWithin the range
EPS · AdjustedFY2025$3.00 to $3.15Raised twice$3.22Above the range
RevenueFY2024$61.00B to $64.00BGiven once$63.63BWithin the range

PFE in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.